UBS Group AG - GRACELL BIOTECHNOLOGIES INC ownership

GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 34 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of GRACELL BIOTECHNOLOGIES INC
ValueSharesWeighting
Q3 2023$6,659
-36.1%
2,312
-15.5%
0.00%
Q2 2023$10,424
+118.3%
2,736
+6.6%
0.00%
Q1 2023$4,775
-42.3%
2,567
-28.6%
0.00%
Q4 2022$8,273
-36.4%
3,597
-7.8%
0.00%
Q3 2022$13,000
+30.0%
3,903
+138.7%
0.00%
Q4 2021$10,000
+100.0%
1,635
+287.4%
0.00%
Q2 2021$5,0004220.00%
Other shareholders
GRACELL BIOTECHNOLOGIES INC shareholders Q3 2022
NameSharesValueWeighting ↓
Vivo Capital, LLC 10,881,144$31,337,6953.43%
Sio Capital Management, LLC 2,081,216$5,993,9021.86%
Pivotal bioVenture Partners Investment Advisor LLC 1,375,000$3,960,0001.58%
TCG Crossover Management, LLC 3,038,889$8,752,0001.29%
Logos Global Management LP 2,525,000$7,272,0000.97%
SPHERA FUNDS MANAGEMENT LTD. 1,531,497$4,410,7110.80%
Orbimed Advisors 9,308,726$26,809,1310.57%
GREAT POINT PARTNERS LLC 579,667$1,669,4410.30%
Temasek Holdings (Private) Ltd 9,901,940$28,517,5870.17%
TANG CAPITAL MANAGEMENT LLC 159,087$458,1710.06%
View complete list of GRACELL BIOTECHNOLOGIES INC shareholders